A retrospective study to evaluate the effect of Nivolumab in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated in a national early access program (EAP)
Latest Information Update: 13 Oct 2017
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Expanded access; Therapeutic Use
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.